Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
5.90
+0.03 (0.51%)
At close: Aug 4, 2025, 4:00 PM
5.85
-0.05 (-0.83%)
After-hours: Aug 4, 2025, 7:16 PM EDT

Company Description

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

The company’s lead product candidate is ersodetug, a human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.

It also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 2 clinical trial for the chronic treatment of diabetic macular edema.

The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.

Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Rezolute, Inc.
Rezolute logo
CountryUnited States
Founded2010
IndustryBiotechnology
SectorHealthcare
Employees59
CEONevan Elam

Contact Details

Address:
275 Shoreline Drive, Suite 500
Redwood City, California 94065
United States
Phone650 206 4507
Websiterezolutebio.com

Stock Details

Ticker SymbolRZLT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJuly - June
Reporting CurrencyUSD
CIK Code0001509261
CUSIP Number76200L309
ISIN NumberUS76200L3096
Employer ID27-3440894
SIC Code2834

Key Executives

NamePosition
Nevan Charles Elam J.D.Founder, Chief Executive Officer, Principal Financial Officer and Acting Chairman of the Board
Daron G. Evans M.B.A., M.S.Chief Financial Officer
Dr. Brian Kenneth Roberts M.D.Chief Medical Officer
Michael R. DeperroSenior Vice President and Head of Operations
Dr. Davelyn Eaves Hood M.B.A., M.D.Director and Head of Scientific and Patient Affairs
Michael CovarrubiasSenior Vice President and Head of Program & Portfolio Management
Chris MilksVice President and Head of Finance
Dr. Raj Agrawal M.D.Vice President and Head of Ophthalmological Clinical Development
Robyn SweinhartVice President and Head of Quality
Erin O'BoyleSenior Vice President and Head of Clinical Operations

Latest SEC Filings

DateTypeTitle
Jul 18, 20258-KCurrent Report
Jul 17, 2025S-3Registration statement under Securities Act of 1933
Jun 13, 20258-K/A[Amend] Current report
Jun 13, 20258-KCurrent Report
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
Apr 28, 20258-KCurrent Report
Apr 23, 20258-KCurrent Report
Apr 23, 2025424B5Filing
Apr 23, 2025424B5Filing